Cell Line Models
Applied StemCell’s CRISPR/Cas9 cell line modeling experts have successfully engineered more than 500 distinct cell line models in > 100 distinct mammalian cell lines from different species. We use highly optimized and efficient CRISPR/Cas9 genome editing strategies and protocols to engineer or correct mutations in a variety of cell lines such as cancer cells, hard-to-transfect cells, blood lineage cells, stem cells and many more with a > 97% success rate.
Our full service cell line editing portfolio includes:
-
Targeting vector construction and validation; cell transfection and selection; single cell cloning; expansion and cryopreservation
-
Custom deliverables: choice of homozygous and/or heterozygous clones; point mutation with/without silent mutation
Cell Line Model Generation Categories
CRISPR/Cas9
.jpg)
CRISPR/Cas9 Cell Line
Service - Hematopoietic Cells
(Jurkat and TF-1)
CRISPR/Cas9 Genome
Editing in
Stem Cells
Products and Services
| Catalog ID# | Product Name | Price | ||
|---|---|---|---|---|
$7,000.00 | ||||
$10,000.00 | ||||
Supporting Material
Brochure/Flyer:
Posters:
Webinar:
Would you like more information on our blood lineage cells editing services? Watch our webinar on CRISPR-based gene editing in blood lineage and blood-derived cell lines, presented by Dr. Jimmy Tai, Senior Scientist and Group Leader at Applied StemCell:
"CRISPR/Cas9 Editing in Blood Lineage Cells: Guidelines to enhance your CRISPR gene editing process"
TARGATT™ and CRISPR/Cas9 modified induced pluripotent stem cells (iPSCs) for in vitro genetic disease modeling (December 2015)
Publications
Applied StemCell publications and citations:
-
Selvan, N., George, S., Serajee, F. J., Shaw, M., Hobson, L., Kalscheuer, V. M., ... & Schwartz, C. E. (2018). O-GlcNAc transferase missense mutations linked to X-linked intellectual disability deregulate genes involved in cell fate determination and signaling. Journal of Biological Chemistry, jbc-RA118.
-
Smalley, E. (2018). FDA warns public of dangers of DIY gene therapy. https://doi.org/10.1038/nbt0218-119
-
Chai, S., Wan, X., Ramirez-Navarro, A., Tesar, P. J., Kaufman, E. S., Ficker, E., ... & Deschênes, I. (2018). Physiological genomics identifies genetic modifiers of long QT syndrome type 2 severity. The Journal of clinical investigation, 128(3).
-
Boi, S., Ferrell, M. E., Zhao, M., Hasenkrug, K. J., & Evans, L. H. (2018). Mouse APOBEC3 expression in NIH 3T3 cells mediates hypermutation of AKV murine leukemia virus. Virology, 518, 377-384. https://doi.org/10.1016/j.virol.2018.03.014.
-
Molinski, S. V., et al. (2017). Orkambi® and amplifier co‐therapy improves function from a rare CFTR mutation in gene‐edited cells and patient tissue. EMBO Molecular Medicine, e201607137.
-
Petrovic, P. B. (2017). Myosin Phosphatase Rho-interacting Protein Regulates DDR1-mediated Collagen Tractional Remodeling (Doctoral dissertation, University of Toronto (Canada)).
-
Peng, L., Zhang, H., Hao, Y., Xu, F., Yang, J., Zhang, R., ... & Chen, C. (2016). Reprogramming macrophage orientation by microRNA 146b targeting transcription factor IRF5. EBioMedicine, 14, 83-96.
-
Hu, J. K., Crampton, J. C., Locci, M., & Crotty, S. (2016). CRISPR-mediated Slamf1Δ/Δ Slamf5Δ/Δ Slamf6Δ/Δ triple gene disruption reveals NKT cell defects but not T follicular helper cell defects. PloS one, 11(5), e0156074.
-
Smalley, E. (2016). CRISPR mouse model boom, rat model renaissance. Nature Biotechnology. 34, 893–894.
-
Baker, M. (2014). Gene editing at CRISPR speed. Nature biotechnology, 32(4), 309-313.
CRISPR Technology:
-
Ran, FA, et al. (2013). Cell, 154(6), 1380-1389.
-
Wang, H., et al. (2013). Cell, 153(4), 910–918. http://doi.org/10.1016/j.cell.2013.04.025
-
Mali, P., et al. (2013). Nature Biotechnology, 31(9), 833–838. http://doi.org/10.1038/nbt.2675
-
Ran, FA, et al. (2013) Nature Protocols, 2281-2308 doi:10.1038/nprot.2013.143
-
Yang, H., et al. (2013). Cell, 154(6), 1370-1379.
-
Cho, SW., et al. (2013). Nature biotechnology, 31(3), 230-232.
-
Cheng, AW., et al. (2013). Cell Research, 23(10), 1163–1171.
-
Cong, L., et al. (2013). Science (New York, N.Y.), 339(6121), 819–823.
-
Jinek, M., et al. (2013). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557905/
-
Gilbert, LA., et al. (2013). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770145/
-
Hsu, PD., et al. (2013). Nature Biotechnology, 31(9), 827–832.
-
Ramalingam, S., et al. (2013). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663103/
-
Shen, B., et al. (2013). Cell Research, 23(5), 720–723.
-
Fu, Y., et al. (2013). Nature Biotechnology, 31(9), 822–826.
-
Pattanayak, V., et al. (2013). Nature biotechnology, 31(9), 839-843.
-
Koyanagi-Aoi, M., et al. (2013). PNAS, 110(51), 20569–20574.
-
Mali, P., et al. (2013). Nature Methods, 10(10), 957–963.
-
Bikard, D., et al. (2013). Nucleic Acids Research, 41(15), 7429–7437.
-
Yang, L., et al. (2013). Nucleic Acids Research, 41(19), 9049–9061. http://doi.org/10.1093/nar/gkt555
-
Hou, Z., et al. (2013). PNAS, 110(39), 15644-15649.
-
Qi, LS., et al. (2013). Cell, 152(5), 1173-1183.
-
Pennisi, E. (2013). The CRISPR Craze. Science, 341(6148), 833-836.
-
Shalem, O., et al. (2014). Science, 343(6166), 84-87.
-
Carroll, D. (2013). Staying on target with CRISPR-Cas. Nature biotechnology,31(9), 807.
-
Walsh, RM., & Hochedlinger, K. (2013). PNAS, 110(39), 15514-15515.
-
Chen, F., et al. (2011). Nature methods, 8(9), 753-755.
-
Sanjana, NE., et al. (2012) Nature protocols, 7(1), 171-192.
-
Kim, H., et al. (2011). Surrogate reporters for enrichment of cells with nuclease-induced mutations. Nature methods, 8(11), 941-943.
-
van Nierop, GP., et al. (2009). Nucleic acids research, 37(17), 5725-5736.
-
Zhang, SC., et al. (2001). In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nature biotechnology, 19(12), 1129-1133.
Technical Details
More than 500 unique cell line models engineered from >100 distinct parental cell lines!
| Cell Type | Modification Type |
| Cancer Cell Lines | Knockout Point Mutation Insertion |
| Human iPSCs | Knockout Point Mutation Insertion |
| Human ES | Insertion |
| Primate iPSCs | Insertion |
| Human Primary Cells | Knockout Insertion |
| Human Fibroblasts | Point Mutation |
| Mouse Fibroblasts | Point Mutation |
| Rat Thyrocytes | Knockout |
|
Selected Cell Lines From > 100 distinct parental cell lines engineered A-549 BEAS-2B BT-474 HaCaT HBE Huh7 MCF-10A OCCM-30 RPE-1 SK-MEL-31 Tert-RPE U-2 OS 786-O CHLA-10 A-375 Gist-T1 DLD-1 HCT-116 HEK293 HEK293T HeLa HepG2 4T1 C2C12 cTEC MWCL-1 BCWM-1 H929 Jurkat K562 KHYG-1 LAD2 MM.1s NCI-H929 T2 cells TF-1 HT1080 HT29 KBM-7 KN12-Luc LnCap MDA-MB231 NCI-H2228 RKO TC32 SCC35 SH-SY5Y ES Cells iPSCs |
Partial list of cell line engineering projects completed by Applied StemCell:
-
Knockout modifications
-
Gene knock-in (KI): locus-specific gene insertion; KI into safe harbor locus; gene tagging/ reporter gene insertion
-
Gene overexpression
-
Conditional / inducible gene expression; promoter modifications
-
Gene editing/ correction, including single base changes
-
Gene replacement; gene therapy
-
Gene fusion/ translocation
-
Removal of viral sequences
-
Stable cell lines / immortalization
Applications:
-
Recombinant protein production in CHO cells
-
Disease model in human cell lines for drug discovery
-
Gene therapy in diseased cell line
-
Target selection for drug discovery
-
High throughput preclinical screening of candidate drugs and toxicity assays
-
Custom engineering cell lines for deriving diagnostic reference standards and materials
-
Generation of TARGATT™ master cell lines by inserting an attP "docking site" for site-specific gene knock-in
For large DNA/ transgene insertion in cell lines, please refer to the TARGATT™ cell line editing services. The TARGATT™ integrase-based technology offers site-specific gene knock-in and is complementary to CRISPR/Cas9 technology. Both these technologies offers a broader scope for engineering physiologically predictive and advanced cell line models.
We also offer lentivirus-based stable cell line generation for difficult-to-handle cell lines: integration-free lentivirus for CRISPR-lentivirus gene knockout; broad tropism lentiviruses for efficient stable gene knock-in.
Comprehensive Technology Platforms for Genome Editing
|
Methods |
Technical Advantage |
|
TARGATT™ phiC31 integrase |
|
|
CRISPR / Cas9 |
|
